Centers for Disease Control and Prevention

Adult Respiratory Syncytial Virus (RSV) Session

Camille Kotton, MD

Chair, Adult RSV Work Group

Advisory Committee on Immunization Practices (ACIP)

June 21, 2023
2

Adult RSV Work Group Membership

ACIP Voting Members

Camille Kotton (Chair)

Keipp Talbot

Sarah Long

Ex Officio Members

Rachel Zhang (FDA)

Judy Beeler (FDA)

Nicholas Geagan (FDA)

Nadine Peart Akindele (FDA)

Sonnie Kim (NIH/NIAID)

Jeffrey Kelman (CMS)

Valerie Marshal (OIDP)

CDC Co-Leads

Michael Melgar

Amadea Britton

Consultants

Robert Atmar (Baylor College of 

Medicine)

Helen Chu (University of Washington)

Peter Donofrio (Vanderbilt University)

Marie Griffin (Vanderbilt University)

Cynthia Lucero-Obusan (Veterans Health 

Admin.)

Tracy Ruckwardt (NIH/NIAID)

Jonathan Temte (University of Wisconsin)

Liaisons

Kenneth Schmader (AGS)

Vidya Sundareshan (ACP)

Gretchen LaSalle (AAFP)

April Killikelly (NACI, PHAC)

Winnie Su (NACI, PHAC)

Katherine Williams (APTR)

Ruth Lynfield (NFID)

Jennifer Heath (AIM)

Steven Pergam (IDSA)
3

CDC Contributors

Coronavirus and Other Respiratory 

Viruses Division

Lauren Roper

Fiona Havers 

Meredith McMorrow

Diya Surie

Jennifer DeCuir

Mila Prill

Amanda Payne

Natalie Thornburg

Melissa Coughlin

Jefferson Jones

Katherine Fleming-Dutra

Ismael Ortega Sanchez

Immunization Safety Office

Anne Hause

David Shay

Christine Olson

Immunization Services Division

Neil Murthy

Patricia Wodi

Andrew Leidner

Jamison Pike
4

Recap of Adult RSV session, February 2023

▪ Economic analysis of RSV vaccination in older adults (CDC model)

▪ Comparison of economic analyses of RSV vaccination in older adults (CDC 

model vs. industry models)

▪ Evidence to Recommendations framework for use of two RSV vaccines 

(GSK and Pfizer products) in older adults 
5

Recent work group discussion

▪ Review of Season 2 safety and efficacy data from main phase 3 trials of RSV 

vaccines, as well as coadministration study results (with influenza vaccines)

▪ Update to GRADE and Evidence to Recommendations for both RSV 

vaccines, inclusive of Season 2 data

▪ Update to economic analyses of RSV vaccination in older adults, inclusive 

of Season 2 data

▪ Ethics considerations of different RSV vaccine policy recommendations
6

Recent work group discussion

▪ Possible policy recommendations for RSV vaccination of U.S. older adults

– Should RSV vaccines be recommended for U.S. adults aged ≥65 years?

– Should RSV vaccines be recommended for U.S. adults aged 60–64 

years?
7

Agenda: Wednesday June 21, 2023

▪ Pfizer safety and efficacy update, including coadministration 

results

▪ GSK safety and efficacy update, including coadministration 

results

▪ Economic analysis of RSV vaccination among U.S. older 

adults

▪ Comparison of RSV vaccination economic analyses 

performed by U. Michigan/CDC, Pfizer, and GSK

▪ Update to Evidence to Recommendations framework for 

Pfizer and GSK RSV vaccines

▪ Clinical considerations for use of RSV vaccines in U.S. older 

adults

Dr. Alejandra Gurtman (Pfizer)

Dr. Leonard Friedland (GSK)

Dr. David Hutton (U. Michigan)

Dr. Ismael Ortega Sanchez (CDC)

Dr. Michael Melgar (CDC)

Dr. Amadea Britton (CDC)